Suggested remit: To appraise the clinical and cost effectiveness of teprotumumab within its marketing authorisation for treating thyroid eye disease.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6432
Provisional Schedule
- Expected publication:
- 13 August 2025
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Amgen Limited (teprotumumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- British Thyroid Foundation
- The Thyroid Trust
- Professional groups
- Royal College of Ophthalmologists
- Royal College of Physicians
- Society for Endocrinology
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2025 - 23 July 2025 | Draft guidance: 1 |
| 03 June 2025 | Committee meeting |
| 03 April 2025 | Declaration of interests |
| 29 October 2024 | Invitation to participate |
| 18 July 2024 - 15 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6432 |
| 18 July 2024 | In progress. Scoping commenced. |
| 10 April 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual